Trends in Cell Biology, Journal Year: 2024, Volume and Issue: unknown
Published: Sept. 1, 2024
Language: Английский
Advanced Materials, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 10, 2025
Abstract Cancer immunotherapy, which leverages immune system components to treat malignancies, has emerged as a cornerstone of contemporary therapeutic strategies. Yet, critical concerns about the efficacy and safety cancer immunotherapies remain formidable. Nanotechnology, especially polymeric nanoparticles (PNPs), offers unparalleled flexibility in manipulation‐from chemical composition physical properties precision control nanoassemblies. PNPs provide an optimal platform amplify potency minimize systematic toxicity broad spectrum immunotherapeutic modalities. In this comprehensive review, basics polymer chemistry, state‐of‐the‐art designs from physicochemical standpoint for encompassing vaccines, situ vaccination, adoptive T‐cell therapies, tumor‐infiltrating cell‐targeted antibodies, cytokine therapies are delineated. Each immunotherapy necessitates distinctively tailored design strategies nanoplatforms. The extensive applications PNPs, investigation their mechanisms action enhanced particularly focused on. profiles clinical research progress discussed. Additionally, forthcoming developments emergent trends nano‐immunotherapeutics poised transform treatment paradigms into clinics explored.
Language: Английский
Citations
5
Nature Reviews Drug Discovery, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 28, 2025
Language: Английский
Citations
4
npj Vaccines, Journal Year: 2025, Volume and Issue: 10(1)
Published: Jan. 3, 2025
Language: Английский
Citations
2
Journal of Controlled Release, Journal Year: 2025, Volume and Issue: 379, P. 327 - 343
Published: Jan. 14, 2025
Language: Английский
Citations
1
Aggregate, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 2, 2025
ABSTRACT Prostate cancer is an epithelial malignancy with a high incidence among elderly men. Photochemistry‐based dye photodrugs (known as photosensitizers) offer promising clinical approach for treating tumors. These agents work by inducing immunogenic cell death (ICD), which activates antitumor immune response. This favored owing to its minimal invasiveness, low toxicity, and efficiency. However, the immunosuppressive microenvironment of characteristics “cold” tumors significantly restricts efficacy photodrugs. Developing advanced nanocarrier system deliver agonists efficient drug delivery tumor lesion sites reshape crucial in practice. Therefore, this study, we designed integrin‐targeted, activatable nano photodrug co‐assembly agonist (RPST@IMQ) enhancing photoimmunotherapy prostate via reprogramming tumor‐associated macrophages. The active‐targeted nanosystem enhanced dosage at site through systemic administration. High doses glutathione cleaved disulfide bonds RPST@IMQ, releasing imiquimod (IMQ). Under photoirradiation, generated significant singlet oxygen eliminate cells, thereby ICD activate responses. Simultaneously, released IMQ reprograms M2‐type macrophages (TAMs) into M1‐type TAMs tumor‐killing capabilities, converting “hot” conversion enhances therapeutic against primary distant vivo. study offers new insights development innovative, smart, enhance anticancer outcomes.
Language: Английский
Citations
1
Advanced Materials, Journal Year: 2024, Volume and Issue: unknown
Published: Aug. 28, 2024
Personalized cancer vaccines based on tumor cell lysates offer promise for immunotherapy yet fail to elicit a robust therapeutic effect due the weak immunogenicity of antigens. Autophagosomes, obtained from pleural effusions and ascites patients, have been identified as abundant reservoirs neoantigens that exhibit heightened immunogenicity. However, their potential personalized constrained by suboptimal lymphatic-targeting performances challenges in antigen-presenting endocytosis. Here,a reinforced biomimetic autophagosome-based (BAPs) nanovaccine generated precisely amalgamating autophagosome-derived two types adjuvants capable targeting lymph nodes is developed potently antitumor immunity. The redox-responsive BAPs facilitate cytosolic vaccine opening within cells, thereby exposing antigens stimulate strong immune response. evoke broad-spectrum T-cell responses, culminating effective eradication 71.4% established tumors. Notably, vaccination triggers enduring responses confer protection, with 100% mice shielded against rechallenge significant reduction incidence 87.5%. Furthermore, synergize checkpoint blockade therapy inhibit growth poorly immunogenic breast model. approach presents powerful formula high versatility immunotherapy.
Language: Английский
Citations
5
Small Methods, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 22, 2025
Abstract Current tumor vaccines suffer from inadequate immune responsive due to the insufficient release of antigens, low infiltration, and immunosuppressive microenvironment. DNA nanostructures with their ability precisely engineer, controlled release, biocompatibility, capability augment immunogenicity microenvironment, have gained significant attention for potential revolutionize vaccine designing. This review summarizes various applications in construction situ cancer vaccines, which can generate tumor‐associated antigens directly damaged tumors immune‐stimulation. The mechanisms components are listed, specific strategies constructing using explored underlying action elucidated. immunogenic cell death (ICD) induced by chemotherapeutic agents, photothermal therapy (PTT), photodynamic (PDT), radiation (RT) related building systematically summarized. different immunotherapy elaborated, exerts precise, long‐lasting, robust responses. current challenges future prospectives proposed. provides a holistic understanding evolving role development.
Language: Английский
Citations
0
Journal of Controlled Release, Journal Year: 2025, Volume and Issue: 379, P. 757 - 767
Published: Jan. 25, 2025
Language: Английский
Citations
0
Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(2), P. 198 - 198
Published: Feb. 5, 2025
Tumor metastasis, the spread of cancer cells from primary site to distant organs, remains a formidable challenge in oncology. Central this process is involvement subcellular organelles, which undergo significant functional and structural changes during metastasis. Targeting these specific organelles offers promising avenue for enhanced drug delivery metastasis therapeutic efficacy. This precision increases potency reduces potential off-target effects. Moreover, by understanding role each organelle treatments can be designed disrupt metastatic at multiple stages, cell migration establishment secondary tumors. review delves deeply into tumor processes their connection with organelles. In order target biomembranes, cell-penetrating peptides, localization signal aptamers, small molecules, various other strategies have been developed. review, we will elucidate targeting look forward prospects domain.
Language: Английский
Citations
0
Chinese Chemical Letters, Journal Year: 2025, Volume and Issue: unknown, P. 110970 - 110970
Published: Feb. 1, 2025
Language: Английский
Citations
0